

1 Full title: **The spread and burden of the COVID-19 pandemic in sub-Saharan Africa: comparison between**
2 **predictions and actual data and lessons learned.**

3 Short title: **Comparison between predictions and actual data on the COVID-19 pandemic in sub-Saharan**
4 **Africa.**

5 Christophe Dongmo Fokoua-Maxime¹, Yahia Bellouche², Dillonne Ngonpong Tchigui-Ariolle³, Tchana Loic
6 Tchato-Yann⁴, Simeon Pierre Choukem⁵

7

8 ¹University of New York State – University at Albany School of Public Health, Albany, NY, United States,

9 ²Brest University Hospital Center, Brest, France, ³School of Health Sciences, Catholic University of Central

10 Africa, Yaoundé, Cameroon, ⁴University of Yaoundé 1 Faculty of Medicine and Biomedical Sciences, ⁵Faculty

11 of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon.

12

13 ***Correspondance**

14 Christophe Dongmo Fokoua-Maxime

15 Email: fokouamaxime@yahoo.fr

16

17

18

19

20

21

22

23

24

25

26

27

28

29

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 ABSTRACT

31 **Introduction.** Sub-Saharan Africa (SSA) was predicted to be severely affected by the coronavirus disease
32 2019 (COVID-19) pandemic, but the actual data seem to have contradicted these forecasts. This study attempted
33 to verify this observation by comparing predictions against actual data on the spread and burden of the COVID-
34 19 pandemic in SSA.

35 **Methods.** Focused on the period from March 1st to September 30th, 2020, we compared (1) the predicted
36 interval dates when each SSA country would report 1 000 and 10 000 COVID-19 cases, to the actual dates when
37 these numbers were attained, as well as (2) the daily number of predicted versus actual COVID-19 cases.
38 Further, we calculated the case fatality ratio of the COVID-19 infection in SSA, and the correlation coefficient
39 between the weekly average number of confirmed COVID-19 cases reported by each country and the weekly
40 average stringency index of its anti-COVID-19 policy measures.

41 **Results.** 84.61% (33) and 100% (39) of the 39 SSA countries for which predictions were made did not reach a
42 total of 1 000 and 10 000 confirmed COVID-19 cases at the predicted interval dates. The daily number of
43 confirmed COVID-19 cases was lower than the one projected for all SSA countries. The case fatality ratio of the
44 COVID-19 infection in SSA was 3.42%. Among the 44 SSA countries for which the correlation could be
45 estimated, it was negative for 17 (38.6 %) of them.

46 **Conclusions.** The natural characteristics of SSA and the public health measures implemented might partly
47 explain that the actual data were lower than the predictions on the COVID-19 pandemic in SSA, but the low
48 case ascertainment and the numerous asymptomatic cases did significantly influence this observation.

49 **Key words:** COVID-19 pandemic, sub-Saharan Africa, comparison, predictions, actual data.

50

51

52

53

54

55 INTRODUCTION

56 The Coronavirus disease 2019 (COVID-19) outbreak was classified as a pandemic on March 11th, 2020, owing
57 to its lightning proliferation and the ominous prospect that the sudden massive influx of critically ill patients
58 would overwhelm healthcare systems (1). Thenceforward, the world has experienced several COVID-19 surges
59 and as of the April 30th, 2022, the planet has cumulatively reported 513 109 654 confirmed cases and 6 260 020
60 deaths (2). The pandemic has caused substantial disruptions in daily activities and has wreaked havoc
61 socioeconomic systems across the globe.

62 The first case of COVID-19 infection on the African continent was detected in Egypt on February 12th, 2020
63 (3,4). As of April 30th, 2022, African countries have recorded a cumulative total of 11 895 452 confirmed
64 COVID-19 cases and 253 791 deaths (2). At the onset of the COVID-19 pandemic in sub-Saharan Africa, the
65 rapid progression of the sanitary crisis constrained local stakeholders to constantly make several important
66 policy decisions on a short notice. Historical data could not be used to this effect given the novelty of the
67 COVID-19 infection. Therefore, to raise alarms and build public health strategies, public health officials and
68 stakeholders had to rely on predictive models. The latter had predicted that the COVID-19 pandemic would
69 severely affect Sub-Saharan Africa (SSA), owing to its high levels of air traffic with China, the predominance
70 of ill-equipped and short-staffed hospitals, the lack of research and testing laboratories, and the presence of
71 unhealthy populations who live mostly in overcrowded urban centers with limited access to handwashing, but
72 who interact through physical contacts-based sociocultural living customs (5). In the light of these concerning
73 prospects, the World Health Organization (WHO) alerted on April 17th, 2020 that Africa would become the next
74 epicenter of the COVID-19 pandemic (6,7).

75 Nevertheless, after the first waves of the COVID-19 pandemic had subsided, several reports highlighted that
76 SSA had defied these dire predictions (8). However, to date, no study has verified this observation. More
77 importantly, the world is currently experiencing a resurgence of COVID-19 cases driven by new and more
78 virulent viral strains (9,10). It is therefore critical to scientifically evaluate if SSA did truly defy the grim
79 forecasts on the COVID-19 pandemic, because if that were the case, it would be urgent to identify the
80 population and environmental characteristics as well as the public health interventions which contributed to that
81 positive outcome, as they would form the core of efficient strategies which would abate current and future
82 COVID-19 occurrences. The proposed research undertook that endeavor; we compared the predictions against

83 the actual data on the spread and burden of the COVID-19 pandemic in sub-Saharan Africa, and we discussed
84 the potential reasons for the differences observed.

85 **METHODS**

86 **Data sources**

87 We conducted a cross-sectional study which compared predictions to actual data on the spread and burden of
88 COVID-19 in SSA during the period spanning from March 1st to September 30th, 2020. The predictions on the
89 burden of COVID-19 in SSA were obtained from the MRC Centre for Global Infectious Disease Analysis at
90 Imperial College London (11). The MRC Centre for Global Infectious Disease Analysis at Imperial College
91 London used data from the European Centre for Disease Control database to predict for each country within the
92 next 28 days: [a] the daily number of confirmed COVID-19 cases; [b] the number of deaths; [c] the number of
93 individuals needing oxygen or mechanical ventilation; and [d] the impact of changing the current intervention
94 policy (11). The source of the predictions on the spread of COVID-19 in SSA was a publication by Pearson et
95 al. from the Center for Mathematical Modeling of Infectious Diseases of the London School of Hygiene &
96 Tropical Medicine (1). Pearson et al. predicted the 95% confidence interval (CI) dates at which each SSA
97 country would report a total of 1 000 and 10 000 COVID-19 cases (1). The starting point of their predictions
98 was the day when each country had at least 25 COVID-19 cases reported in the World Health Organization
99 (WHO) Situation Reports (SITREPs); for countries who had not reached this number by the March 22nd, 2020,
100 they used the number of cases reported in the WHO SITREPs as of March 23rd, 2020, 10:00 Central European
101 Summer Time (1).

102 The WHO SITREPs are reports based on actual COVID-19 data provided by the health authorities of each
103 country (12). Each SITREP presents the following: [a] the daily number of new confirmed COVID-19 cases; [b]
104 the total number of confirmed COVID-19 cases reported since the date that a country started sending reports; [c]
105 the number of days since the last day that a country reported a COVID-19 case ; [d] the daily number of deaths
106 attributed to COVID-19; [e] the total number of deaths attributed to COVID-19 since the date that the country
107 started sending reports; and finally, [f] the updated COVID-19 transmission classification level of each country
108 (level 1 = no case reported, level 2 = sporadic cases, level 3 = clusters of cases, and level 4 = community
109 transmission) (12). From the WHO SITREPs, we extracted the actual dates at which each SSA country reported
110 1 000 and 10 000 confirmed COVID-19 cases. In instances where these exact numbers were unavailable, we
111 retrieved the earliest dates at which they were surpassed. In instances where these numbers were never reached,

112 we presented the total number of confirmed COVID-19 cases reported at the date this paper was submitted for
113 peer review and publication. Of note, Pearson et al. did not compute predictions for Botswana, Burundi,
114 Comoros, Guinea-Bissau, Malawi, Mali, Lesotho, Sao-Tome & Principe, and Sierra Leone (1), whereas they all
115 belong to SSA. In a sake of completeness, we retrieved the total number of confirmed COVID-19 cases reported
116 by these countries on April 30th and May 31st, 2020, respectively. These dates were chosen because Person et al.
117 had predicted that most SSA countries would report a total of 1 000 COVID-19 cases by the end of April and 10
118 000 cases couple of weeks later (1). In line with our primary objective of comparing predictions to actual data,
119 we further scavenged the WHO SITREPs to find the actual dates at which these specific countries reported these
120 numbers of cases.

121 To complement our research, we also evaluated the impact of the anti-COVID-19 policy measures implemented.
122 The latter were valued through the Stringency Index (SI). The SI is a metric conceived as part of the Oxford
123 COVID-19 Government Response Tracker (OxCGRT) project and has been previously described in details (13).
124 In brief, the OxCGRT project is an endeavor undertaken by Oxford University to measure the strictness of the
125 anti-COVID-19 policy measures that were enacted by the authorities of each country. To provide a general
126 appreciation of each country's governance, the OxCGRT project performed multiple different combinations of
127 several individual policy measures to create a myriad of distinct indices. Among these indices, the SI combines
128 nine of the response measures: school closures, workplace closures, cancellation of public events, restrictions on
129 public gatherings, closures of public transport, stay-at-home requirements, public information campaigns,
130 restrictions on internal movements, and international travel controls. Based on its level of enforcement, each of
131 the response measures was given a score, and these individual scores were added together to yield the SI of each
132 country. The SI was proportional to the strictness of each country's anti-COVID-19 response, and a SI of 100
133 indicated the strictest response.

134 **Data Analyses**

135 To compare predictions to actual data on the spread of COVID-19, we assessed if the actual dates at which each
136 SSA country reached a total of 1 000 and 10 000 COVID-19 cases belonged to the respective 95% CI dates
137 predicted by Pearson et al. (1). A country was said to have defied the predictions if the actual date did not
138 belong to the predicted 95% CI. To compare predictions and actual data on the burden of COVID-19, we first
139 performed a graphical comparison between the predicted and confirmed daily number of COVID-19 cases, from
140 the day that each country first reported COVID-19 cases in the WHO SITREPs until September 30th, 2020.

141 Then, we calculated the case fatality ratio of the COVID-19 infection (proportion of deaths among all the
142 identified confirmed cases of COVID-19 (14)) in SSA during the period spanning from March 1st to September
143 30th, 2020. To evaluate the impact of the anti-COVID-19 policy measures implemented, we computed the
144 correlation coefficient between the weekly average SI of anti-COVID-19 policy measures at time t, and the
145 weekly average number of confirmed COVID-19 cases at time t + 14 days, along with the 95% CI of the said
146 correlation coefficient. We considered a 14-day lag between the 2 metrics because it takes approximately one
147 incubation period to see the effects of newly implemented anti-COVID-19 policy measures (15). Further, we
148 used weekly averages instead of daily numbers to account for the delays in case ascertainment and reporting.
149 Finally, to prevent any violation of the assumption of independence required for any correlation analyses, we
150 used the repeated measures correlation technique available via the rmcrr package of the statistical software R
151 (16). Of note, our report aligns with the Strengthening The Reporting of Observational studies in Epidemiology
152 (STROBE) guidelines (Annex 1) (17).

153 **Ethics**

154 Our study was exempt from Institutional Review Board approval since we used data already collected and
155 published.

156 **RESULTS**

157 **Predictions versus actual data on the spread of COVID-19**

158 Among the 39 countries included in the publication by Pearson et al. (1) 33 (84.61%) did not reach a total of 1
159 000 COVID-19 cases at the predicted interval dates (table 1a). Of these, three (7.70%) countries reached 1000
160 confirmed cases only in 2021 (Mauritius: 31 March 2021, Seychelles: 23 January 2021, and Tanzania: 2 August
161 2021). All (100%) of the 39 countries included in the publication by Pearson et al. [1] did not reach a total of 10
162 000 COVID-19 cases at the predicted interval dates (table 1a). No (0%) country reported 10 000 cases before
163 the predicted interval dates, 16 (41%) countries reached 10 000 cases only in 2021, and as of April 30th, 2022, 4
164 (10.25%) countries still have not reached 10 000 confirmed COVID-19 cases (Chad: 7411 cases, Eritrea: 9734
165 cases, Niger: 7434 cases, and Liberia: 8928 cases). Of the 9 countries not included in the publication by Pearson
166 et al. (1), none (0%) of them either reported a total of 1000 on April 30th, 2020 or 10 000 COVID-19 cases on
167 May 31st, 2020(table 1b). As of April 30th, 2022, 4 (44.44%) of these countries still have not reached 10 000

168 confirmed COVID-19 cases (Comoros: 8100 cases, Guinea-Bissau: 8202 cases, Sao Tome & Principe: 5957
169 cases, and Sierra Leone: 7681 cases).

170 **Predictions versus actual data on the burden of COVID-19**

171 From March to September 2020, except for Burundi, Botswana, and Seychelles, the actual daily number of
172 confirmed COVID-19 cases reported by each SSA country was lower than the number predicted (figure 1). At
173 the continental level, the total number of actual confirmed COVID-19 cases was 1 126 341, which is far lower
174 than the total number of predicted cases (median 10 504 027 IQR: 9 936 984 – 11 170 105). The cumulative
175 case fatality ratio of the COVID-19 infection in SSA from March to September 2020 was approximately 3.42%.

176 **Impact of the anti-COVID-19 policy measures implemented**

177 Among the 44 countries for which the correlation could be calculated, a negative correlation was found for 17
178 (38.6%) of them, and none of these negative correlation coefficients had a 95% CI which excluded 0. The
179 correlation coefficient for Comoros, Equatorial Guinea, Guinea-Bissau, and Sao Tome & Principe were not
180 estimated because data on the stringency index for these countries are not available in the Oxford Coronavirus
181 Government Response Tracker.

182 **DISCUSSION**

183 Overall, most SSA countries did not report 1 000 and 10 000 cases at the predicted dates, and the actual
184 numbers of COVID-19 cases were lower than those predicted. These results might be explained by the
185 limitations of the statistical models which yielded these predictions. Additionally, specific local population and
186 environmental characteristics as well as the low case ascertainment might have had a mitigating effect.

187 The prediction model of the MRC Centre for Global Infectious Disease Analysis at Imperial College London
188 was built on estimates of severity obtained from data from China and Europe, and model parameters obtained
189 from data from China and the United Kingdom (11). On the other hand, Pearson et al. considered that the
190 reproductive number R (which is the number of ancillary cases that one case would generate if in contact with a
191 completely susceptible population (18)) would be 2, that the dispersion estimate k (which is the variance of R
192 over the mean of R and quantifies whether a set of observed cases are clustered or dispersed when compared to
193 cases following a standard negative binomial distribution (19)) would be 0.58, and that the serial interval (which
194 is the time that elapses between two consecutive cases of an infectious disease (20)) would be normally

195 distributed with a mean of 4.7 ± 2.9 days (1). These model parameters all originated from populations which
196 substantially differ from SSA populations in terms of composition, density, living customs, and health status, all
197 of which impact the dynamic of the COVID-19 pandemic. Furthermore, Abbot et al. acknowledged that data
198 were scarce at the time they estimated R and k, and they pointed that their results would be significantly
199 impacted if new data became available (21). Lastly, Rai et al. also indicated that their study calculating the serial
200 interval had “numerous limitations”, including the high risk of bias due to the multiplicity of data collection
201 protocols, the impossibility to identify every potential contact an individual had, and the numerous unaccounted
202 asymptomatic travelers (22).

203 Pearson et al. also assumed that no public health interventions would be implemented (1). However, as of
204 March 31st, 2020, more than 50% of SSA countries had already imposed travel restrictions to prevent the
205 importation of the SARS-CoV-2 virus (23). Of note, previous evidence had reported that travel bans were
206 effective in preventing the importation of COVID-19 (24,25). Pearson et al. also assumed that both the early
207 epidemic trends and the reporting fraction among actual cases and delay would remained constant, that there
208 would always be sufficient unreported infections to continue the transmission, and that new cases would
209 represent a sample from both identified and previously unidentified transmission chains (1). Nevertheless, for
210 such assumptions to be true, the living conditions and the dynamic of the COVID-19 infection must have also
211 remained unchanged. However, living conditions were and are still constantly modified to match the momentum
212 of the COVID-19, and the pandemic is an ever-changing outbreak which outsmarts all assumptions and
213 predictive models.

214 In SSA, specific population and environmental characteristics also mitigated the epidemic pace of the COVID-
215 19 pandemic which was determined by the rate of introduction of the SARS-CoV-2 virus, its environmental
216 proliferation, and the maintenance of the COVID-19 infection (14).

217 Evidence have demonstrated that the SARS-CoV-2 virus was introduced in SSA via international flights and
218 tourists’ arrivals (14). Data show that 71% (34 out 48) of SSA countries had imposed travel bans on flights
219 arriving from high-risk areas for COVID-19 several days before (indicated in green and as negative numbers in
220 figure 2a) the first confirmed COVID-19 case(s) was(were) identified. As a result, tourists’ arrivals significantly
221 decreased from March to June 2020 and culminated at a record -91% in April 2020 compared to the same month
222 in 2019 (figure 2b). Previous evidence had demonstrated that non-pharmacologic interventions of this type can
223 abate the spread of the COVID-19 infection (26). Indeed, efficient bureaucracy and guidance happening prior to

224 high infection rates is known to have produced the greatest benefits against COVID-19 (14). Therefore, these
225 early interventions potentially mitigated the rate of introduction of the SARS-CoV-2 virus in SSA.

226 The rate of introduction of the SARS-CoV-2 virus was also determined by the susceptibility of the exposed
227 population. The Centers for Disease Control and Prevention (CDC) described that the people at high risk for
228 COVID-19 infection were those of older age (above 65 years), and those with health risk factors such as obesity
229 and/or severe medical conditions like diabetes (27). Population pyramids (figure 3a) built using data from the
230 2020 United Nations Population Prospects (28) show that subjects aged 0 to 14 years represent 40.55% of the
231 SSA population, whereas those aged 65 and older represent only 3.5%. This is quite low compared to North
232 America, Europe, and Asia where the 65 and older represent 16%, 18.8 % and 19.6% of the total population
233 respectively. In addition, data compiled from the Global Burden of Disease Study 2017 (29) reveals that except
234 for malnutrition, HIV/AIDS, and tuberculosis, SSA reported lower mortality rates from obesity, smoking,
235 cardiovascular disease, chronic kidney disease, chronic respiratory diseases, chronic liver disease, cancers,
236 diabetes, and outdoor pollution, compared to other continents where the COVID-19 pandemic was more severe
237 (figure 3b). At last, it is hypothesized that SSA populations possess a cross-protection against COVID-19
238 because of anterior infections by epidemic coronaviruses or other germs (14,30,31).

239 Climate was also considered a major determinant of the COVID-19 pandemic in SSA. Indeed, it was advanced
240 that the warmer and wetter weather of SSA tempered the environmental proliferation of the SARS-CoV-2 virus
241 in the region (32). However, these evidence were not welcomed by all (14). This skepticism probably arose
242 because the temperatures required to kill the SARS-CoV-2 virus are far beyond what humans can tolerate (33).
243 Nevertheless, we still believe that the climate had a mitigating effect on the COVID-19 pandemic in SSA, not
244 by a direct effect on the virus, but rather by an indirect effect on the immunity through the influence that climate
245 has on Vitamin D (Vit-D) levels. Indeed, data from the Solar Atlas (34) shows that SSA is the region which
246 receives the highest amount of solar energy, and this translates into high levels of Vit-D in local populations
247 (35). In turn, Vit-D is known to significantly improve human immune capacities (36).

248 Despite these potential protective characteristics, SSA still reported COVID-19 cases which means that the virus
249 was introduced in the region but did not spread at the rates predicted. This hints that the transmissibility of the
250 COVID-19 infection among people was also affected. Non-pharmacologic interventions are known to abate the
251 spread of COVID-19 (26), and the governments of SSA countries implemented preventive measures early on
252 during the first wave of the pandemic (figures 2a and 2b). Other determinants of the transmissibility of the
253 COVID-19 infection are the connectivity, the travel time, and the habitual population movements between cities

254 and regions (14). During the last 50 years, the increase in road constructions across SSA significantly improved
255 the connectivity and reduced the travel time between localities (14). However, the daily commute is not custom
256 in SSA. Therefore, the spread of the COVID-19 infection might have been limited to narrow geographic areas.
257 The transmissibility of the COVID-19 infection is also impacted by the prevalence of severe cases. Indeed,
258 severe cases are more prone to transmit the COVID-19 infection because of their higher viral load, and they are
259 also more prone to die of the infection (37). The case fatality ratio of COVID-19 in SSA was approximately
260 3.42%, which is much lower compared than the case fatality ratio reported on other continents (38–40).
261 Evidence suggest that the lower susceptibility of SSA populations to COVID-19 might have resulted in most
262 cases being asymptomatic (41), meaning less contagious. Therefore, SSA might have hosted mostly less severe
263 cases, which translated into a lower probability of transmission of the COVID-19 infection in the region.

264 The actual number of COVID-19 cases in SSA might also be this low because not all cases were reported.
265 Nations with highly technical and infrastructural abilities were first to possess diagnostic equipment for
266 COVID-19, and they prioritized their local populations. Consequently, SSA countries, which do not possess
267 such capabilities, were left on endless waiting lists for supply, which substantially limited their testing
268 capacities. As evidence, statistics on the number of daily COVID-19 tests per 1 000 individuals show that on 30
269 June 2020 data were missing for several SSA countries (42). This is corroborated by serologic studies conducted
270 in a limited number of SSA countries and which have reported a seroprevalence between 1.8% and 45.1% (43–
271 46). The low frequency of COVID-19 case ascertainment in SSA might also be due to the high number of
272 asymptomatic subjects. Indeed studies have suggested that the lower susceptibility to COVID-19 conferred by
273 the youth of SSA populations resulted in most cases being asymptomatic (41), and hence they were not tested
274 and thus not reported.

275 Our study presents certain limitations. The cross-sectional design did not allow us to capture the temporal
276 relationship between the different indicators and the occurrence of COVID-19 cases, which precludes any
277 discussion about causation. However, it would have been unethical to conduct a prospective study in which
278 humans would have been purposefully deprived of life-saving preventive measures against COVID-19.
279 Therefore, a cross-sectional study was indicated. Another limitation is the small number of countries (17 out of
280 44) for which there was a negative correlation between the weekly average number of COVID-19 cases and the
281 weekly average SI, which questions the true efficacy of the prevention efforts deployed inside SSA countries.
282 Of note, the scientists who designed the index cautioned that it does not measure the actual level of
283 implementation of the anti-COVID-19 policy measures which make the index (13). Nevertheless, studies had

284 demonstrated the efficacy of non-pharmacologic measures against COVID-19, and the SI was the sole metric
285 available in that regard for our use. Finally, the vast array of the potential contributors to the spread of COVID-
286 19, the unconsidered peculiarities of each SSA country, and the use of continental level rather individual level
287 health data, point to the necessity to exercise caution in the interpretation of these results which were pooled
288 across several very dissimilar geographic and socioeconomic settings.

289 Our research does have several strengths. It responds to the long-lasting call for a comprehensive analysis of the
290 differences between the predictions and the actual data on the COVID-19 pandemic in SSA. In addition, our
291 analysis also included the countries for which predictions were not made. Finally, we discussed the population
292 and environmental characteristics as well as the public health interventions which may have contributed to the
293 positive outcome observed. Substantial efforts should be made to reinforce the preventive measures against
294 COVID-19 in SSA. Besides, resources should be allocated to strategies aiming to maintain the baseline health of
295 populations in the world in general, and in SSA in particular. Finally, the grim prospect of future similar public
296 health crisis calls for a thorough upgrade of the quantity and quality of diagnostic, treatment, research, and drug
297 development facilities across the globe.

298 **CONCLUSION**

299 The actual figures of COVID-19 were lower than the predictions for all SSA countries, but the low case
300 ascertainment and the numerous asymptomatic cases have greatly influenced this observation. Exploring the
301 hypotheses suggested to understanding the reasons for more asymptomatic cases in SSA could help build
302 stronger strategies to respond to future COVID-19 resurgences as well as other viral epidemics. Finally, there is
303 an urgent need for a massive upscaling of diagnostic, treatment, and research capabilities in SSA and across the
304 globe.

305 **Acknowledgments.** We thank Professor Martin Tenniswood for his comments and suggestions.

306 **Competing interests.** I have read the journal's policy and the authors of this manuscript have the following
307 competing interests: Simeon Pierre Choukem who is co-author of this paper is also an Academic Editor for
308 PLOS ONE journal. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
309 Further, the conclusions made herein are those of the authors and do not necessarily represent the position of the
310 institutions to which they belong.

311 **Authors' Contributions.** CDFM and SPC conceptualized the idea. CDFM devised the study, conducted
312 the analysis, interpreted the results, and wrote the first draft of the manuscript. YB, DNTA, TLTY, and SPC
313 thoroughly reviewed the manuscript for data completeness, methodologic accuracy, and grammatical
314 correctness. All authors had full access to the data in the study and accept responsibility to publish the results.

315 **Funding.** None.

316 **Data Sharing.** Data will be made available by the corresponding author upon a signed data access
317 agreement.

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340 REFERENCES

- 341 1. Pearson CA, Schalkwyk CV, Foss AM, O'Reilly KM, Team SM and AR, Group CC 19 working, et al.
342 Projected early spread of COVID-19 in Africa through 1 June 2020. *Eurosurveillance*. 2020 May
343 7;25(18):2000543.
- 344 2. COVID Live - Coronavirus Statistics - Worldometer [Internet]. [cited 2022 Jan 23]. Available from:
345 <https://www.worldometers.info/coronavirus/>
- 346 3. Egypt announces first Coronavirus infection - Egypt Today [Internet]. [cited 2020 Jun 11]. Available
347 from: <https://www.egypttoday.com/Article/1/81641/Egypt-announces-first-Coronavirus-infection>
- 348 4. Coronavirus: Beijing orders 14-day quarantine for returnees - BBC News [Internet]. [cited 2020 Jun 11].
349 Available from: <https://www.bbc.com/news/world-asia-china-51509248>
- 350 5. Zhang F, Karamagi H, Nsenga N, Nanyunja M, Karinja M, Amanfo S, et al. Predictors of COVID-19
351 epidemics in countries of the World Health Organization African Region. *Nat Med*. 2021 Sep 3;1–7.
- 352 6. Bellamy D. Africa will be next epicentre of coronavirus, says WHO [Internet]. *euronews*. 2020 [cited
353 2020 Jun 12]. Available from: [https://www.euronews.com/2020/04/18/africa-will-be-next-epicentre-of-](https://www.euronews.com/2020/04/18/africa-will-be-next-epicentre-of-coronavirus-says-who)
354 [coronavirus-says-who](https://www.euronews.com/2020/04/18/africa-will-be-next-epicentre-of-coronavirus-says-who)
- 355 7. Coronavirus: Africa could be next epicentre, WHO warns - BBC News [Internet]. [cited 2020 Jun 11].
356 Available from: <https://www.bbc.com/news/world-africa-52323375>
- 357 8. Salyer SJ, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif M, et al. The first and second waves
358 of the COVID-19 pandemic in Africa: a cross-sectional study. *The Lancet*. 2021 Apr 3;397(10281):1265–
359 75.
- 360 9. New Strain of COVID-19 Is Driving South Africa's Resurgence [Internet]. *US News & World Report*.
361 [cited 2021 Mar 1]. Available from: [https://www.usnews.com/news/world/articles/2020-12-21/new-](https://www.usnews.com/news/world/articles/2020-12-21/new-strain-of-covid-19-is-driving-south-africas-resurgence)
362 [strain-of-covid-19-is-driving-south-africas-resurgence](https://www.usnews.com/news/world/articles/2020-12-21/new-strain-of-covid-19-is-driving-south-africas-resurgence)
- 363 10. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern [Internet]. [cited 2021 Nov 30].
364 Available from: [https://www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern)
365 [cov-2-variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern)
- 366 11. Imperial College COVID-19 LMIC Reports [Internet]. [cited 2021 Oct 31]. Available from: [https://mrc-](https://mrc-ide.github.io/global-lmic-reports/)
367 [ide.github.io/global-lmic-reports/](https://mrc-ide.github.io/global-lmic-reports/)
- 368 12. Coronavirus Disease (COVID-19) Situation Reports [Internet]. [cited 2021 Mar 23]. Available from:
369 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
- 370 13. Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A global panel database of
371 pandemic policies (Oxford COVID-19 Government Response Tracker). *Nature Human Behaviour*. 2021
372 Mar 8;1–10.
- 373 14. Rice BL, Annapragada A, Baker RE, Bruijning M, Dotse-Gborgbortsi W, Mensah K, et al. Variation in
374 SARS-CoV-2 outbreaks across sub-Saharan Africa. *Nature Medicine*. 2021 Mar;27(3):447–53.
- 375 15. Violato C, Violato EM, Violato EM. Impact of the stringency of lockdown measures on covid-19: A
376 theoretical model of a pandemic. *PLOS ONE*. 2021 Oct 5;16(10):e0258205.
- 377 16. Bakdash JZ, Marusich LR. Repeated Measures Correlation. *Frontiers in Psychology*. 2017;8:456.
- 378 17. Elm E von, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the
379 Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting
380 observational studies. *Journal of Clinical Epidemiology*. 2008 Apr 1;61(4):344–9.

- 381 18. Dietz K. The estimation of the basic reproduction number for infectious diseases. *Stat Methods Med Res.*
382 1993;2(1):23–41.
- 383 19. Index of dispersion. In: Wikipedia [Internet]. 2020 [cited 2021 May 16]. Available from:
384 https://en.wikipedia.org/w/index.php?title=Index_of_dispersion&oldid=991953492
- 385 20. Rai B, Shukla A, Dwivedi LK. Estimates of serial interval for COVID-19: A systematic review and meta-
386 analysis. *Clin Epidemiol Glob Health.* 2021;9:157–61.
- 387 21. Abbott S, Hellewell J, Munday J, CMMID nCoV working group, Funk S. The transmissibility of novel
388 Coronavirus in the early stages of the 2019-20 outbreak in Wuhan: Exploring initial point-source
389 exposure sizes and durations using scenario analysis. *Wellcome Open Res.* 2020;5:17.
- 390 22. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-19 in 391
391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis.*
392 2020 Aug;20(8):911–9.
- 393 23. Connor P. More than nine-in-ten people worldwide live in countries with travel restrictions amid COVID-
394 19 [Internet]. Pew Research Center. [cited 2022 Mar 27]. Available from:
395 [https://www.pewresearch.org/fact-tank/2020/04/01/more-than-nine-in-ten-people-worldwide-live-in-](https://www.pewresearch.org/fact-tank/2020/04/01/more-than-nine-in-ten-people-worldwide-live-in-countries-with-travel-restrictions-amid-covid-19/)
396 [countries-with-travel-restrictions-amid-covid-19/](https://www.pewresearch.org/fact-tank/2020/04/01/more-than-nine-in-ten-people-worldwide-live-in-countries-with-travel-restrictions-amid-covid-19/)
- 397 24. Grépin KA, Ho TL, Liu Z, Marion S, Piper J, Worsnop CZ, et al. Evidence of the effectiveness of travel-
398 related measures during the early phase of the COVID-19 pandemic: a rapid systematic review. *BMJ*
399 *Global Health.* 2021 Mar 1;6(3):e004537.
- 400 25. Gwee SXW, Chua PEY, Wang MX, Pang J. Impact of travel ban implementation on COVID-19 spread in
401 Singapore, Taiwan, Hong Kong and South Korea during the early phase of the pandemic: a comparative
402 study. *BMC Infectious Diseases.* 2021 Aug 11;21(1):799.
- 403 26. Li Y, Campbell H, Kulkarni D, Harpur A, Nundy M, Wang X, et al. The temporal association of
404 introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R)
405 of SARS-CoV-2: a modelling study across 131 countries. *Lancet Infect Dis.* 2021 Feb;21(2):193–202.
- 406 27. CDC. Coronavirus Disease 2019 (COVID-19) [Internet]. Centers for Disease Control and Prevention.
407 2020 [cited 2020 Jun 30]. Available from: [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html)
408 [precautions/people-with-medical-conditions.html](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html)
- 409 28. World Population Prospects - Population Division - United Nations [Internet]. [cited 2021 Jun 29].
410 Available from: <https://population.un.org/wpp/Download/Standard/Population/>
- 411 29. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national
412 burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease
413 Study 2017. *The Lancet.* 2020 Feb 29;395(10225):709–33.
- 414 30. Simeni Njonnou SR, Noumedem Anangmo NC, Kemta Lekpa F, Noukeu Njinkui D, Enyama D,
415 Ngongang Ouankou C, et al. The COVID-19 Prevalence among Children: Hypotheses for Low Infection
416 Rate and Few Severe Forms among This Age Group in Sub-Saharan Africa. *Interdiscip Perspect Infect*
417 *Dis.* 2021;2021:4258414.
- 418 31. Tso FY, Lidenge SJ, Peña PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. High prevalence of pre-existing
419 serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in
420 sub-Saharan Africa. *International Journal of Infectious Diseases.* 2021 Jan 1;102:577–83.
- 421 32. Mecnas P, Bastos RT da RM, Vallinoto ACR, Normando D. Effects of temperature and humidity on the
422 spread of COVID-19: A systematic review. *PLoS One.* 2020;15(9):e0238339.
- 423 33. Abraham JP, Plourde BD, Cheng L. Using heat to kill SARS-CoV-2. *Rev Med Virol.* 2020 Jul 2;e2115.

- 424 34. Global Solar Atlas [Internet]. [cited 2021 Jun 29]. Available from:
425 <https://globalsolaratlas.info/download/world>
- 426 35. Mogire RM, Mutua A, Kimita W, Kamau A, Bejon P, Pettifor JM, et al. Prevalence of vitamin D
427 deficiency in Africa: a systematic review and meta-analysis. *Lancet Glob Health*. 2020 Jan;8(1):e134–42.
- 428 36. Hewison M. An update on vitamin D and human immunity. *Clin Endocrinol (Oxf)*. 2012 Mar;76(3):315–
429 25.
- 430 37. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission,
431 Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*. 2020 Aug
432 25;324(8):782–93.
- 433 38. Millar JA, Dao HDN, Stefopoulos ME, Estevam CG, Fagan-Garcia K, Taft DH, et al. Risk factors for
434 increased COVID-19 case-fatality in the United States: A county-level analysis during the first wave.
435 *PLOS ONE*. 2021 Oct 14;16(10):e0258308.
- 436 39. Soneji S, Beltrán-Sánchez H, Yang JW, Mann C. Population-level mortality burden from novel
437 coronavirus (COVID-19) in Europe and North America. *Genus*. 2021 Apr 16;77(1):7.
- 438 40. Rampal S, Rampal L, Jayaraj VJ, Pramanick A, Choolani M, Liew BS, et al. The epidemiology of
439 COVID-19 in ten Southeast Asian countries. *Med J Malaysia*. 2021 Nov;76(6):783–91.
- 440 41. Wang E, Brar K. COVID-19 in Children: An Epidemiology Study from China. *The Journal of Allergy
441 and Clinical Immunology in Practice*. 2020 Jun;8(6):2118.
- 442 42. COVID-19 Data Explorer [Internet]. Our World in Data. [cited 2022 May 2]. Available from:
443 <https://ourworldindata.org/coronavirus-data-explorer>
- 444 43. Fai KN, Corine TM, Bebell LM, Mboringong AB, Nguimbis EBPT, Nsaibirni R, et al. Serologic response
445 to SARS-CoV-2 in an African population. *Scientific African*. 2021 Jul;12:e00802.
- 446 44. Abdella S, Riou S, Tessema M, Assefa A, Seifu A, Blachman A, et al. Prevalence of SARS-CoV-2 in
447 urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave
448 of the pandemic. *eClinicalMedicine* [Internet]. 2021 May 1 [cited 2022 Mar 30];35. Available from:
449 [https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370\(21\)00160-7/fulltext](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00160-7/fulltext)
- 450 45. Müller SA, Wood RR, Hanefeld J, El-Bcheraoui C. Seroprevalence and risk factors of COVID-19 in
451 healthcare workers from 11 African countries: a scoping review and appraisal of existing evidence. *Health
452 Policy and Planning*. 2021 Nov 2;czab133.
- 453 46. Barrie MB, Lakoh S, Kelly JD, Kanu JS, Squire JS, Koroma Z, et al. SARS-CoV-2 antibody prevalence
454 in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey. *BMJ
455 Global Health*. 2021 Nov 1;6(11):e007271.
- 456
- 457
- 458
- 459
- 460

Table 1 : Predictions versus actual data on the spread of COVID-19 in SSA. 1a. Predicted and actual dates at which sub-Saharan African countries included in the publication of Pearson et al.,¹ reported a cumulative total of 1000 and 10 000 confirmed COVID-19, respectively.

Country	Actual date for 1000 cases (number of cases) ^a	Predicted interval date for 1000 cases ^b	Actual date for 10 000 cases (number of cases) ^c	Predicted interval date for 10 000 cases ^d
Angola	29 Jul 2020 (1000)	12 Apr 2020 – 17 May 2020	28 Oct 2020 (10 074)	28 Apr 2020 – 12 Jun 2020
Benin	26 Jun 2020 (1017)	08 Apr 2020 – 16 May 2020	18 Aug 2021 (10 183)	24 Apr 2020 – 09 Jun 2020
Burkina Faso	06 Jul 2020 (1000)	31 Mar 2020 – 15 Apr 2020	24 Jan 2021 (10 038)	14 Apr 2020 – 01 May 2020
Cabo Verde	26 Jun 2020 (1003)	11 Apr 2020 – 16 May 2020	18 Nov 2020 (10,000)	27 Apr 2020 – 11 Jun 2020
Cameroon	18 Apr 2020 (1017)	27 Mar 2020 – 17 Apr 2020	19 Jun 2020 (10 638)	12 Apr 2020 – 03 May 2020
CAR	01 Jun 2020 (1011)	07 Apr 2020 – 14 May 2020	14 Jun 2021 (10 047)	23 Apr 2020 – 09 Jun 2020
Chad	27 Aug 2020 (1004)	11 Apr 2020 – 18 May 2020	30 April 2022 (7411)	28 Apr 2020 – 12 Jun 2020
Congo	23 Jun 2020 (1087)	06 Apr 2020 – 13 May 2020	06 Apr 2021 (10 084)	22 Apr 2020 – 06 Jun 2020
Côte d’Ivoire	24 Apr 2020 (1004)*	02 Apr 2020 – 02 May 2020	03 Jul 2020 (10 244)	16 Apr 2020 – 24 May 2020
DRC	11 May 2020 (1024)	01 Apr 2020 – 19 Apr 2020	29 Aug 2020 (10 007)	15 Apr 2020 – 06 May 2020
Djibouti	26 Apr 2020 (1008)*	11 Apr 2020 – 18 May 2020	13 Apr 2021 (10 077)	27 Apr 2020 – 12 Jun 2020
Equatorial Guinea	24 May 2020 (1043)	06 Apr 2020 – 10 May 2020	9 Sept 2021 (10 284)	21 Apr 2020 – 04 Jun 2020
Eritrea	27 Dec 2020 (1039)	11 Apr 2020 – 17 May 2020	30 April 2022 (9734)	02 May 2020 – 11 Jun 2020
Eswatini	07 Jul 2020 (1011)	07 Apr 2020 – 15 May 2020	04 Jan 2021 (10 138)	23 Apr 2020 – 10 Jun 2020
Ethiopia	31 May 2020 (1063)	04 Apr 2020 – 01 May 2020	20 Jul 2020 (10 207)	18 Apr 2020 – 26 May 2020
Gabon	14 May 2020 (1004)	06 Apr 2020 – 10 May 2020	18 Jan 2021 (10 019)	21 Apr 2020 – 05 Jun 2020
Gambia	08 Aug 2020 (1090)	10 Apr 2020 – 19 May 2020	12 Dec 2021 (10 034)	28 Apr 2020 – 12 Jun 2020
Ghana	20 Apr 2020 (1042)	01 Apr 2020 – 17 Apr 2020	11 Jun 2020 (10 201)	15 Apr 2020 – 03 May 2020
Guinea	27 Apr 2020 (1094)*	06 Apr 2020 – 15 May 2020	12 Sep 2020 (10 020)	22 Apr 2020 – 09 Jun 2020
Kenya	21 May 2020 (1029)	03 Apr 2020 – 24 Apr 2020	13 Jul 2020 (10 105)	18 Apr 2020 – 12 May 2020
Liberia	13 Jul 2020 (1010)	08 Apr 2020 – 14 May 2020	30 April 2022 (7434)	24 Apr 2020 – 09 Jun 2020

Madagascar	07 Jun 2020 (1026)	08 Apr 2020 – 25 Apr 2020	29 Jul 2020 (10 104)	21 Apr 2020 – 11 May 2020
Mauritania	09 Jun 2020 (1049)	06 Apr 2020 – 14 May 2020	09 Dec 2020 (10 105)	23 Apr 2020 – 07 Jun 2020
Mauritius	31 Mar 2021 (1028)	06 Apr 2020 – 01 May 2020	30 August 2021 (10 196)	19 Apr 2020 – 25 May 2020
Mozambique	07 Jul 2020 (1012)	13 Apr 2020 – 19 May 2020	11 Oct 2020 (10 001)	29 Apr 2020 – 14 Jun 2020
Namibia	17 Jul 2020 (1032)	05 Apr 2020 – 13 May 2020	17 Sep 2020 (10 078)	22 Apr 2020 – 07 Jun 2020
Niger	17 Jun 2020 (1016)	11 Apr 2020 – 19 May 2020	30 April 2022 (8928)	28 Apr 2020 – 12 Jun 2020
Nigeria	25 Apr 2020 (1095)	23 Mar 2020 – 18 Apr 2020	01 Jun 2020 (10 162)	09 Apr 2020 – 04 May 2020
Rwanda	30 Jun 2020 (1001)	02 Apr 2020 – 22 Apr 2020	13 Jan 2021 (10 122)	16 Apr 2020 – 11 May 2020
Senegal	02 May 2020 (1024)	23 Mar 2020 – 12 Apr 2020	31 Jul 2020 (10 106)	07 Apr 2020 – 29 Apr 2020
Seychelles	23 Jan 2021 (1033)	05 Apr 2020 – 08 May 2020	25 May 2021 (10 740)	20 Apr 2020 – 02 Jun 2020
Somalia	11 May 2020 (1054)*	06 Apr 2020 – 12 May 2020	21 Mar 2021 (10 085)	27 Apr 2020 – 06 Jun 2020
South Africa	28 Mar 2020 (1170)*	26 Mar 2020 – 15 Apr 2020	11 May 2020 (10 015)	09 Apr 2020 – 03 May 2020
South Sudan	09 May 2020 (1111)*	05 Apr 2020 – 14 May 2020	25 Mar 2021 (10 048)	22 Apr 2020 – 08 Jun 2020
Togo	07 Aug 2020 (1001)	30 Mar 2020 – 19 Apr 2020	30 Mar 2021 (10 249)	15 Apr 2020 – 05 May 2020
Uganda	09 Jul 2020 (1000)	10 Apr 2020 – 08 May 2020	14 Oct 2020 (10 069)	24 Apr 2020 – 31 May 2020
Tanzania	02 Aug 2021 (1017)	06 Apr 2020 – 02 May 2020	10 October 2021 (25 846) [#]	20 Apr 2020 – 26 May 2020
Zambia	28 May 2020 (1057)	09 Apr 2020 – 15 May 2020	19 Aug 2020 (10 218)	25 Apr 2020 – 11 Jun 2020
Zimbabwe	14 Jul 2020 (1034)	11 Apr 2020 – 17 May 2020	01 Dec 2020 (10 129)	28 Apr 2020 – 11 Jun 2020

^a Originates from the World Health Organization (WHO) situation reports (SITREPs) and it is the date at which each country reported a cumulative total of 1000 confirmed COVID-19 cases ; in instances where this exact number could not be found is reported the earliest date at which this number was surpassed, and in instances where this number was never reached is reported the date at which this paper was submitted for peer review and publication. ^b Originates from the publication by Pearson et al.,¹ and it is the 95% confidence interval of the date at which each country was predicted to have reported a cumulative total of 1000 confirmed COVID-19 cases. ^c Originates from the WHO SITREPs and it is the date at which each country reported a cumulative total of 10 000 confirmed COVID-19 cases ; in instances where this exact number could not be found is reported the earliest date at which this number was surpassed, and in instances where this number was never reached is reported the date at which this paper was submitted for peer review and publication. ^d Originates from the publication by Pearson et al.,¹ and it is the 95% confidence interval of the date at which each country was predicted to have reported a total of 10 000 confirmed COVID-19 cases. CAR = Central African Republic. DRC = Democratic Republic of Congo. *Countries which fulfilled the predictions made by Pearson et al.¹ [#]The specific date at which Tanzania reported 10 000 COVID-19 cases could not be identified.

Table 1 : Predictions versus actual data on the spread of COVID-19 in SSA. 1b. Total number of confirmed COVID-19 cases reported on 30 April 2020 and 31 May 2020 by the sub-Saharan African countries which were not included in the publication of Pearson et al.,¹ and dates at which these countries reported a cumulative of total of 1000 and 10 000 confirmed COVID-19 cases in the World Health Organization Situation Reports.

Country	Actual cases as of 30 April 2020 ^a	Date for 1000 cases ^b	Actual cases as of 31 May 2020 ^c	Date for 10 000 cases ^d
Botswana	23	08 Oct 2020 (1066)	35	26 Nov 2020 (10 258)
Burundi	11	11 Jan 2021 (1019)	63	16 August 2021 (10 103)
Comoros	01	07 Jan 2021 (1050)	106	30 April 2022 (8100)
Guinea-Bissau	205	18 May 2020 (1032)	1256	30 April 2022 (8202)
Lesotho	0	21 Aug 2020 (1015)	02	15 Feb 2021 (10 254)
Malawi	37	26 Jun 2020 (1005)	284	15 Jan 2021 (11 223)
Mali	490	23 May 2020 (1015)	1265	31 Mar 2021 (10 042)
ST & P	14	07 Dec 2020 (1002)	483	30 April 2022 (5957)
Sierra Leone	124	08 Jun 2020 (1001)	861	30 April 2022 (7681)

^a Originates from the World Health Organization (WHO) situation reports (SITREPs) and is the cumulative total of confirmed COVID-19 cases reported by each country as of 30 April 2020. ^b Originates from the WHO SITREPs and it is the date at which each country reported a cumulative total of 1000 confirmed COVID-19 cases ; in instances where this exact number could not be found is reported the earliest date at which this number was surpassed, and in instances where this number was never reached is reported the date at which this paper was submitted for peer review and publication. ^c Originates from the WHO SITREPs and is the cumulative total of confirmed COVID-19 cases reported by each country as of 31 May 2020. ^d Originates from the WHO SITREPs and it is the date at which each country reported a cumulative total of 10 000 confirmed COVID-19 cases ; in instances where this exact number could not be found is reported the earliest date at which this number was surpassed, and in instances where this number was never reached is reported the date at which this paper was submitted for peer review and publication. ST & P = Sao Tome & Principe.

Table 2. Impact of the anti-COVID-19 policy measures implemented. Repeated measures correlation between the weekly average number of confirmed COVID-19 cases reported and the weekly average stringency index of the anti-COVID-19 policy measures, along with the 95% confidence interval of the correlation coefficient, using data spanning from the first day that each county reported cases in the World Health Organization Situation Reports until September 30th, 2020.

Country	Correlation coefficient ^a	95% confidence interval of the correlation coefficient		P-value
		Upper bound	Lower bound	
Angola	- 0.025 ^b	- 0.46	0.42	0.91
Benin	0.27	- 0.19	0.63	0.21
Botswana	- 0.04 ^b	- 0.48	0.42	0.87
Burkina Faso	- 0.32 ^b	- 0.65	0.13	0.14
Burundi	0.23	- 0.25	0.62	0.31
Cabo Verde	0.20	- 0.26	0.60	0.36
Cameroon	-0.03 ^b	- 0.45	0.40	0.90
Central African Republic	0.21	- 0.24	0.60	0.33
Chad	0.75	0.48	0.90	<0.0001
Comoros			** c	
Congo	0.004	- 0.43	0.43	0.90
Côte d'Ivoire	-0.04 ^b	- 0.46	0.40	0.86
Democratic Republic of Congo	0.30	- 0.15	0.64	0.17
Djibouti	0.27	- 0.17	0.63	0.20
Equatorial Guinea			** c	
Eritrea	- 0.083 ^b	- 0.51	0.40	0.71
Eswatini	0.22	- 0.23	0.60	0.30
Ethiopia	0.002	- 0.43	0.43	0.99
Gabon	0.09	- 0.36	0.50	0.70
Gambia	- 0.18 ^b	- 0.57	0.27	0.40
Ghana	- 0.04 ^b	- 0.50	0.40	0.84
Guinea	0.22	- 0.23	0.60	0.31
Guinea-Bissau			** c	
Kenya	0.07	- 0.37	0.49	0.74
Lesotho	0.10	- 0.44	0.60	0.72
Liberia	0.28	- 0.17	0.63	0.20
Madagascar	0.002	- 0.44	0.44	0.90
Malawi	0.08	- 0.40	0.51	0.72
Mali	0.34	- 0.12	0.70	0.12
Mauritania	0.20	- 0.26	0.60	0.40
Mauritius	- 0.17 ^b	- 0.60	0.28	0.42
Mozambique	0.03	- 0.41	0.46	0.90
Namibia	0.40	- 0.08	0.70	0.08
Niger	0.60	0.20	0.81	0.004
Nigeria	0.23	- 0.21	0.60	0.30
Rwanda	0.01	- 0.42	0.44	0.90
Sao-Tome & Principe			** c	

Senegal	0.02	- 0.40	0.44	0.91
Seychelles	- 0.43 ^b	- 0.73	-0.007	0.04
Sierra Leone	- 0.06 ^b	- 0.50	0.40	0.80
Somalia	0.33	- 0.11	0.70	0.11
South Africa	- 0.06 ^b	- 0.47	0.40	0.80
South Sudan	- 0.11 ^b	- 0.55	0.40	0.70
Tanzania	- 0.20 ^b	- 0.57	0.27	0.40
Togo	- 0.12 ^b	- 0.52	0.32	0.60
Uganda	-0.20 ^b	- 0.60	0.30	0.40
Zambia	0.41	- 0.03	0.71	0.06
Zimbabwe	-0.03 ^b	- 0.44	0.44	0.9

^a Repeated measures correlation coefficient between the daily number of confirmed COVID-19 cases reported by each country and the stringency index of its anti-COVID-19 policy measures. ^b Repeated measures correlation coefficient indicating a negative correlation between the weekly average number of confirmed COVID-19 cases reported by each country and the weekly average stringency index of its anti-COVID-19 policy measures. ^c The repeated measures correlation coefficient between the weekly average number of confirmed COVID-19 cases and the weekly average stringency index anti-COVID-19 policy measures as well as its 95% confidence interval were not estimated because data on the stringency index for these countries are not available in the Oxford Coronavirus Government Response Tracker (OxCGRT)

Annex 1. STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	3
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	3-4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	3
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	3-4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	3-4
Bias	9	Describe any efforts to address potential sources of bias	3-4
Study size	10	Explain how the study size was arrived at	3-4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	3-4

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	3-4
		(b) Describe any methods used to examine subgroups and interactions	3-4
		(c) Explain how missing data were addressed	NA
		(d) If applicable, describe analytical methods taking account of sampling strategy	3-4
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	NA
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	3-4
		(b) Indicate number of participants with missing data for each variable of interest	NA
Outcome data	15*	Report numbers of outcome events or summary measures	3-4
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	4
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	6-9
Generalisability	21	Discuss the generalisability (external validity) of the study results	9
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	10












Figure 1 page 1












Figure 1 page 2












Figure 1 page 3












Figure 1 page 4














Figure 1 page 5




medRxiv preprint doi: <https://doi.org/10.1101/2022.05.04.22274692>; this version posted May 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



Source: World Health Organization Situation Reports ⁶; The MRC Centre for Global Infectious Disease Analysis at Imperial College London. ⁵

Figure 1: The burden of the first wave of the Coronavirus Disease 19 (COVID-19) in sub-Saharan Africa and other continents. **1a.** Comparison between predicted and confirmed daily new cases of COVID-19 in sub-Saharan African countries, from the day that each country first reported COVID-19 cases in the World Health Organization Situation Reports, to September 30th, 2020.




Data source : The Oxford COVID-19 Government Response Tracker (OxCGRT) project ⁷

Figure 2: Public Health response of sub-Saharan African countries against COVID-19. **2a:** Number of days between the date of the first confirmed COVID-19 case(s) and the date at which the governments of sub-Saharan African countries suspended flights originating from the countries which had been declared high risk for COVID-19.

Figure 2a


medRxiv preprint doi: <https://doi.org/10.1101/2022.05.04.22274692>; this version posted May 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



Data source : The United Nations World Tourism Organization ²⁷

Figure 2: Public Health response of sub-Saharan African countries against COVID-19.
2b: Reduction in tourists' arrivals in sub-Saharan African countries in 2020, expressed as the percentage difference in the number of tourists' arrival in the same compared to the same month in 2019.







a



medRxiv preprint doi: <https://doi.org/10.1101/2022.05.04.22274692>; this version posted May 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Source: The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 ²⁰

Figure 3: Susceptibility of populations to COVID-19. **3a:** Population pyramids of sub-Saharan Africa, Asia, Europe, South America, North America, and Oceania.



Source: The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 ²⁰

Figure 3: Susceptibility of populations to COVID-19. **3b:** Annual mortality per 100,000 inhabitants, from specific risk factors and chronic diseases, on the 6 continents.